HYDERABAD, INDIA (Oct’ 14, 2009) – Suven Life Sciences Ltd (Suven) announces today that their clinical candidate SUVN-502 for Alzheimer’s Disease secured several product patents granted at all the key market countries; India (218438), Mexico (257091), South Africa (2005/4043), Singapore (113104), New Zealand (540840), Korea (10-2005-7009512), Eurasia (011320), Australia (2003237599) and Europe (1581492). The granted Product Patent for SUVN-502 in all the countries is valid until June 2023. SUVN-502 is exclusive intellectual property (IP) of Suven and was achieved through the internal discovery research efforts. The granted patent has been validated in all the 9 member countries of Eurasia (Including Russia) and 37 member countries of Europe including major markets like Germany, Switzerland, Denmark, Spain, France, United Kingdom, Italy, Netherlands, Poland, Sweden and Finland.
SUVN-502 completed the Phase-I single ascending & multiple ascending studies at Switzerland and demonstrated to be very safe at all doses tested with excellent bioavailability and half life for potential once in a day treatment. Suven is planning to initiate the clinical Phase-II proof-of-concept (POC) studies during 2010. The company targets launching of SUVN-502 in later part of 2013 or early part of 2014. Other molecules in the same category currently in development include GSK’s molecule presently in Phase-II.
"We are very pleased by the grant of these patents at most of the key market countries for our clinical candidate SUVN-502 which is being developed for CNS disorders in the treatment of cognitive impairment, the unmet medical need. Potential market opportunity for these indications is more than $20 billion globally. Granting of these patents to our clinical candidate SUVN-502 is more timely and relevant now that the candidate is ready to enter into Phase-II proof-of-concept (POC) clinical trials during 2010. SUVN-502 attracted lot of scientific and commercial interest from global pharma companies and few companies initiated due diligence process for potential partnering” says Venkat Jasti CEO of Suven Life Sciences.
For more information on Suven please visit our Web site at http://www.suven.com
Risk Statement:
Except for historical information, all of the statements, expectations and assumptions, including expectations and assumptions, contained in this news release may be forward-looking statements that involve a number of risks and uncertainties. Although Suven attempts to be accurate in making these forward-looking statements, it is possible that future circumstances might differ from the assumptions on which such statements are based. Other important factors which could cause results to differ materially including outsourcing trends, economic conditions, dependence on collaborative partnership programs, retention of key personnel, technological advances and continued success in growth of sales that may make our products/services offerings less competitive;
SUVN-502 completed the Phase-I single ascending & multiple ascending studies at Switzerland and demonstrated to be very safe at all doses tested with excellent bioavailability and half life for potential once in a day treatment. Suven is planning to initiate the clinical Phase-II proof-of-concept (POC) studies during 2010. The company targets launching of SUVN-502 in later part of 2013 or early part of 2014. Other molecules in the same category currently in development include GSK’s molecule presently in Phase-II.
"We are very pleased by the grant of these patents at most of the key market countries for our clinical candidate SUVN-502 which is being developed for CNS disorders in the treatment of cognitive impairment, the unmet medical need. Potential market opportunity for these indications is more than $20 billion globally. Granting of these patents to our clinical candidate SUVN-502 is more timely and relevant now that the candidate is ready to enter into Phase-II proof-of-concept (POC) clinical trials during 2010. SUVN-502 attracted lot of scientific and commercial interest from global pharma companies and few companies initiated due diligence process for potential partnering” says Venkat Jasti CEO of Suven Life Sciences.
For more information on Suven please visit our Web site at http://www.suven.com
Risk Statement:
Except for historical information, all of the statements, expectations and assumptions, including expectations and assumptions, contained in this news release may be forward-looking statements that involve a number of risks and uncertainties. Although Suven attempts to be accurate in making these forward-looking statements, it is possible that future circumstances might differ from the assumptions on which such statements are based. Other important factors which could cause results to differ materially including outsourcing trends, economic conditions, dependence on collaborative partnership programs, retention of key personnel, technological advances and continued success in growth of sales that may make our products/services offerings less competitive;
